Europe Veterinary Vaccines Market

The Europe veterinary vaccines market is projected to reach USD 5.61 billion by 2031, growing from USD 4.08 billion in 2026 at a CAGR of 6.6% during the forecast period.

The Europe veterinary vaccines market is steadily growing, driven by the rising pet ownership, increasing focus on animal welfare, and rising prevalence of infectious and zoonotic diseases. Additionally, a strong regulatory background, government programs in animal health, and increasing sustainable livestock practices are further propelling the demand for vaccination. However, the high development and compliance costs incurred under stringent regulations can slow down growth, thereby making effective management of such factors critical to market expansion.

To know about the assumptions considered for the study download the pdf brochure

Some of the prominent players operating in the Europe veterinary vaccines market include Zoetis (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmbH (Germany), Elanco (US), Virbac (France), Ceva (France), Phibro Animal Health Corporation (US), Hester Biosciences Limited (India), Neogen Corporation (US), HIPRA (Spain), and Vaxxinova International B.V. (Netherlands).

Zoetis (US)

Zoetis develops and manufactures animal health medicines and vaccines, along with diagnostic products, genetic tests, biodevices, and a range of services designed to meet the needs of veterinarians, livestock farmers, and companion animal owners. Zoetis discovers, develops, manufactures, and commercializes a broad portfolio of vaccines and medicines for livestock and companion animals. The company’s major product categories include anti-infectives, vaccines, parasiticides, dermatology, medicated feed additives, other pharmaceuticals, animal health diagnostics, other non-pharmaceuticals, and contract manufacturing & human health. Zoetis operates in North America, Europe, Middle East & Africa, Latin America, and Asia Pacific. The company has robust R&D operations focused on vaccines, devices, data, digital, and other technological innovations.

Merck & Co., Inc. (US)

Merck & Co., Inc. is a global healthcare company that delivers innovative solutions for animal healthcare. The company operates through two divisions: Pharmaceutical and Animal Health. The animal health division discovers, develops, manufactures, and markets a wide range of veterinary pharmaceutical & vaccine products for various animal species. The company operates in over 50 countries across North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. Merck focuses on inorganic growth strategies, such as acquisitions, agreements, and expansion, for its growth in the Europe veterinary vaccines market.

Boehringer Ingelheim International GmbH (Germany)

Boehringer Ingelheim International GmbH is engaged in the research, development, production, and sales of various pharmaceutical products. The company operates through four basic divisions, namely human pharma, animal health, biopharmaceutical contract manufacturing, and discontinued operations. The animal health business division covers a wide range of biological, pharmaceutical, and natural care products for food-producing and companion animals. The company has 151 subsidiaries worldwide. In 2025, it achieved the milestone of four billion doses sold. Also, Boehringer’s strategic partnerships and global reach enhance its ability to meet evolving market demands, positioning it as a leader in the competitive Europe veterinary vaccines sector.

Related Reports:

Europe veterinary vaccines Market by Type (Porcine, Poultry, Livestock, Companion Animals), Technology (Live Attenuated, Inactivated, Toxoid), Route of Administration (Intramuscular, Subcutaneous, Oral), End user (Hospitals, Clinics) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com